Pharmabiz

PharmaTech Expo & LabTech Expo at IPC 2025 to spur future of Indian research with novel instrumentation

Nandita Vijayasimha, Bengaluru Thursday, December 18, 2025, 08:00 Hrs [IST] ...
Pharmabiz

Afghan public health ministerial delegation to explore Indian pharma sector to boost public health

Afghan public health ministerial delegation to explore Indian pharma sector to boost public health: Shardul Nautiyal, Mumbai Thursday, December 18, 2025, 08:00 Hrs [IST] Afghan pu ...
Pharmabiz

Karnataka to appeal against HC order on Jan Aushadhi Kendras in state-run hospitals

Karnataka to appeal against HC order on Jan Aushadhi Kendras in state-run hospitals: Nandita Vijayasimha, Bengaluru Thursday, December 18, 2025, 08:00 Hrs [IST] Karnataka will app ...
Pharmabiz

National Medical Commission mandates new oversight to end unreadable prescriptions

National Medical Commission mandates new oversight to end unreadable prescriptions: Peethaambaran Kunnathoor, Chennai Thursday, December 18, 2025, 08:00 Hrs [IST] Despite existing ...
Pharmabiz

Health ministry issues draft notification with various amendments in MDR, 2017

Health ministry issues draft notification with various amendments in MDR, 2017: Gireesh Babu, New Delhi Thursday, December 18, 2025, 08:00 Hrs [IST] The Union health ministry has ...
Pharmabiz

Agilent Technologies opens India Refurbishment Center to advance sustainable science and affordable innovation

Agilent Technologies opens India Refurbishment Center to advance sustainable science and affordable innovation: Our Bureau, ...
Pharmabiz

UK MHRA approves GSK’s Exdensur to treat asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps

GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...
Pharmabiz

US FDA approves AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab for 1st-line treatment of patients with HER2-positive metastatic breast cancer

US FDA approves AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab for 1st-line treatment of patients with HER2-positive metastatic breast cancer: Cambridge, UK Wednesday, ...
Pharmabiz

Lupin receives EIR from US FDA for its Nagpur injectable facility

Lupin receives EIR from US FDA for its Nagpur injectable facility: Our Bureau, Mumbai Wednesday, December 17, 2025, 13:40 Hrs [IST] Global pharma major Lupin Limited (Lupin) annou ...
Pharmabiz

Lindus Health and Quotient Sciences partner to speed up drug development from first-in-human to pivotal trials

Lindus Health and Quotient Sciences partner to speed up drug development from first-in-human to pivotal trials: Boston Wednesday, December 17, 2025, 17:00 Hrs [IST] Lindus Health, ...
Pharmabiz

Lipocine's PPD phase 3 study oral brexanolone hits 80% enrollment milestone

Lipocine's PPD phase 3 study oral brexanolone hits 80% enrollment milestone: Salt Lake City Wednesday, December 17, 2025, 18:00 Hrs [IST] Lipocine Inc., a biopharmaceutical compan ...
Pharmabiz

EMA committee recommends marketing approval for Lupin’s biosimilar ranibizumab

EMA committee recommends marketing approval for Lupin’s biosimilar ranibizumab: Our Bureau, Mumbai Wednesday, December 17, 2025, 14:40 Hrs [IST] Global pharma major Lupin Limite ...